<?xml version="1.0" encoding="UTF-8"?>
<p class="p">However, both the SCAHAW committee and the CVMA review panel found an increased incidence of foot and leg disorders associated with the long-term administration of rbST [
 <xref rid="B112-animals-05-00361" ref-type="bibr" class="xref">112</xref>,
 <xref rid="B113-animals-05-00361" ref-type="bibr" class="xref">113</xref>]. The CVMA review panel found that cows treated with rbST were at an estimated 55% increase in the risk of developing clinical signs of lameness, and this is now reflected on the Posilac drug label, which states “Cows injected with Posilac may have more enlarged hocks and disorders of the foot region” [
 <xref rid="B132-animals-05-00361" ref-type="bibr" class="xref">132</xref>].
</p>
